Veklury
NDC Package 61958-2902-2
Package Information
Veklury is indicated for the treatment of coronavirus disease 2019 (COVID-19) in adults and pediatric patients (28 days of age and older and weighing at least 3 kg) with positive results of direct severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) viral testing, who are [see Clinical Studies (14)]:Hospitalized, orNot hospitalized and have mild-to-moderate COVID-19, and are at high risk for progression to severe COVID-19, including hospitalization or death. Marketed by Gilead Sciences, Inc., this product is identified by NDC 61958-2902 and is authorized under FDA application NDA214787.
Identification & Billing
- RxCUI: 2284960 - remdesivir 100 MG Injection
- RxCUI: 2367758 - remdesivir 100 MG in 20 mL Injection
- RxCUI: 2367758 - 20 ML remdesivir 5 MG/ML Injection
- RxCUI: 2367758 - remdesivir 100 MG per 20 ML Injection
- RxCUI: 2395502 - Veklury 100 MG Injection
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 61958 - Gilead Sciences, Inc.
- 61958-2902 - Veklury
- 61958-2902-2 - 1 VIAL, SINGLE-DOSE in 1 CARTON / 20 mL in 1 VIAL, SINGLE-DOSE
- 61958-2902 - Veklury
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Other Available Packages
The following commercial packages are registered under the same Product NDC (61958-2902). Click a package code to view its specific billing and regulatory data.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 61958-2902-2 identifies a specific commercial package of 1 vial, single-dose in 1 carton / 20 ml in 1 vial, single-dose of Veklury, labeled by Gilead Sciences, Inc.. This is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
This product code is currently listed as inactive or excluded from the primary directory. It was introduced to the market by Gilead Sciences, Inc. on March 25, 2022. The current certification is valid through October 07, 2025.
How is this Gilead Sciences, Inc. product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 61958290202. Quantities are measured in per "ml or milliliter", products billed per milliliter are usually products measured by liquid volume.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Package segment to maintain the 5-4-2 structure.